Search

Your search keyword '"Choudhury, Gourab"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Choudhury, Gourab" Remove constraint Author: "Choudhury, Gourab"
46 results on '"Choudhury, Gourab"'

Search Results

1. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

3. Role of 18F FDG PET/CT as a novel non-invasive biomarker of inflammation in chronic obstructive pulmonary disease

4. Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

5. Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)

6. Structural Predictors of Lung Function Decline in Young Smokers with Normal Spirometry

7. Identification of critical amino acids in the DNA binding domain of LuxO: Lessons from a constitutive active LuxO.

8. Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial.

11. Implication of Molecular Constraints Facilitating the Functional Evolution of Pseudomonas aeruginosaKPR2 into a Versatile α-Keto-Acid Reductase

12. The effect of different inhaled corticosteroids on airway bacterial load and the microbiome in COPD: a randomized controlled trial

13. COPD Assessment Test (CAT) Score according to the presence/absence of accelerated lung function decline in young adult smokers with normal FEV1

14. Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)

15. NRF2 Activation Reprograms Defects in Oxidative Metabolism to Restore Macrophage Function in Chronic Obstructive Pulmonary Disease

16. NRF2 activation reprogrammes defects in oxidative metabolism to restore macrophage function in COPD

18. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency

19. Reduction of intra-hepatic Z-AAT synthesis by fazirsiran decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency

20. Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

23. Additional file 1 of Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)

24. Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial. (BICS)

28. Consensus Recommendations on the Use of18F-FDG PET/CT in Lung Disease

30. Non-typeable Haemophilus influenzae–Moraxella catarrhalisvaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

35. Quantification of Lung PET Images: Challenges and Opportunities

38. 18F-fluorodeoxyglucose (18FDG) PET pulmonary imaging in COPD

39. Role of Inflammation and Oxidative Stress in the Pathology of Ageing in COPD: Potential Therapeutic Interventions.

42. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.

43. 1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study.

44. Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study.

45. Fazirsiran for Liver Disease Associated with Alpha 1 -Antitrypsin Deficiency.

46. Consensus Recommendations on the Use of 18 F-FDG PET/CT in Lung Disease.

Catalog

Books, media, physical & digital resources